The Utility of Neuroimaging in the Differential Diagnosis of Parkinsonian Syndromes

Abstract

The differential diagnosis of parkinsonian syndromes can be challenging, particularly in early disease stages. However, prognosis and therapeutic regimes are not alike in Parkinson disease and atypical parkinsonism, and thus a correct diagnosis at the earliest possible stage is desirable. Over the past two decades, magnetic resonance imaging and radiotracer-based imaging techniques have proven to be helpful tools to enhance the accuracy of clinical diagnosis in these disorders. Here, we review recent advances in neuroimaging for the differential diagnosis of parkinsonian syndromes.

Keywords

Parkinson disease - atypical parkinsonism - differential diagnosis - neuroimaging

• References

• 1 Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55 (3) 181-184
• 2 Litvan I, Booth V, Wenning GK , et al. Retrospective application of a set of clinical diagnostic criteria for the diagnosis of multiple system atrophy. J Neural Transm 1998; 105 (2-3) 217-227
• 3 Respondek G, Roeber S, Kretzschmar H , et al. Accuracy of the National Institute for Neurological Disorders and Stroke/Society for Progressive Supranuclear Palsy and neuroprotection and natural history in Parkinson plus syndromes criteria for the diagnosis of progressive supranuclear palsy. Mov Disord 2013; 28 (4) 504-509
• 4 Postuma RB, Aarsland D, Barone P , et al. Identifying prodromal Parkinson's disease: pre-motor disorders in Parkinson's disease. Mov Disord 2012; 27 (5) 617-626
• 5 Kalra S, Grosset DG, Benamer HT. Differentiating vascular parkinsonism from idiopathic Parkinson's disease: a systematic review. Mov Disord 2010; 25 (2) 149-156
• 6 Massey LA, Micallef C, Paviour DC , et al. Conventional magnetic resonance imaging in confirmed progressive supranuclear palsy and multiple system atrophy. Mov Disord 2012; 27 (14) 1754-1762
• 7 Wenning GK, Colosimo C, Geser F, Poewe W. Multiple system atrophy. Lancet Neurol 2004; 3 (2) 93-103
• 8 Schwarz J, Weis S, Kraft E , et al. Signal changes on MRI and increases in reactive microgliosis, astrogliosis, and iron in the putamen of two patients with multiple system atrophy. J Neurol Neurosurg Psychiatry 1996; 60 (1) 98-101
• 9 Tolosa E, Wenning G, Poewe W. The diagnosis of Parkinson's disease. Lancet Neurol 2006; 5 (1) 75-86
• 10 Quattrone A, Nicoletti G, Messina D , et al. MR imaging index for differentiation of progressive supranuclear palsy from Parkinson disease and the Parkinson variant of multiple system atrophy. Radiology 2008; 246 (1) 214-221
• 11 Paviour DC, Price SL, Jahanshahi M, Lees AJ, Fox NC. Regional brain volumes distinguish PSP, MSA-P, and PD: MRI-based clinico-radiological correlations. Mov Disord 2006; 21 (7) 989-996
• 12 Messina D, Cerasa A, Condino F , et al. Patterns of brain atrophy in Parkinson's disease, progressive supranuclear palsy and multiple system atrophy. Parkinsonism Relat Disord 2011; 17 (3) 172-176
• 13 Kashihara K, Shinya T, Higaki F. Neuromelanin magnetic resonance imaging of nigral volume loss in patients with Parkinson's disease. J Clin Neurosc 2011; 18: 1093-1096
• 14 Ziegler DA, Wonderlick JS, Ashourian P , et al. Substantia nigra volume loss before basal forebrain degeneration in early Parkinson disease. JAMA Neurol 2013; 70 (2) 241-247
• 15 Jesse S, Kassubek J, Müller HP, Ludolph AC, Unrath A. Signal alterations of the basal ganglia in the differential diagnosis of Parkinson's disease: a retrospective case-controlled MRI data bank analysis. BMC Neurol 2012; 12: 163
• 16 Gröschel K, Hauser TK, Luft A , et al. Magnetic resonance imaging-based volumetry differentiates progressive supranuclear palsy from corticobasal degeneration. Neuroimage 2004; 21 (2) 714-724
• 17 Josephs KA, Tang-Wai DF, Edland SD , et al. Correlation between antemortem magnetic resonance imaging findings and pathologically confirmed corticobasal degeneration. Arch Neurol 2004; 61 (12) 1881-1884
• 18 Ashburner J, Friston KJ. Voxel-based morphometry—the methods. Neuroimage 2000; 11 (6 Pt 1) 805-821
• 19 Pereira JB, Ibarretxe-Bilbao N, Marti MJ , et al. Assessment of cortical degeneration in patients with Parkinson's disease by voxel-based morphometry, cortical folding, and cortical thickness. Hum Brain Mapp 2012; 33 (11) 2521-2534
• 20 Beyer MK, Janvin CC, Larsen JP, Aarsland D. A magnetic resonance imaging study of patients with Parkinson's disease with mild cognitive impairment and dementia using voxel-based morphometry. J Neurol Neurosurg Psychiatry 2007; 78 (3) 254-259
• 21 Biundo R, Formento-Dojot P, Facchini S , et al. Brain volume changes in Parkinson's disease and their relationship with cognitive and behavioural abnormalities. J Neurol Sci 2011; 310 (1-2) 64-69
• 22 Ramírez-Ruiz B, Martí MJ, Tolosa E , et al. Longitudinal evaluation of cerebral morphological changes in Parkinson's disease with and without dementia. J Neurol 2005; 252 (11) 1345-1352
• 23 Yang J, Shao N, Li J, Shang H. Voxelwise meta-analysis of white matter abnormalities in progressive supranuclear palsy. Neurol Sci 2014; 35 (1) 7-14
• 24 Shi HC, Zhong JG, Pan PL , et al. Gray matter atrophy in progressive supranuclear palsy: meta-analysis of voxel-based morphometry studies. Neurol Sci 2013; 34 (7) 1049-1055
• 25 Hauser TK, Luft A, Skalej M , et al. Visualization and quantification of disease progression in multiple system atrophy. Mov Disord 2006; 21 (10) 1674-1681
• 26 Minnerop M, Specht K, Ruhlmann J , et al. Voxel-based morphometry and voxel-based relaxometry in multiple system atrophy-a comparison between clinical subtypes and correlations with clinical parameters. Neuroimage 2007; 36 (4) 1086-1095
• 27 Shigemoto Y, Matsuda H, Kamiya K , et al. In vivo evaluation of gray and white matter volume loss in the parkinsonian variant of multiple system atrophy using SPM8 plus DARTEL for VBM. Neuroimage Clin 2013; 2: 491-496
• 28 Brenneis C, Boesch SM, Egger KE , et al. Cortical atrophy in the cerebellar variant of multiple system atrophy: a voxel-based morphometry study. Mov Disord 2006; 21 (2) 159-165
• 29 Brenneis C, Seppi K, Schocke MF , et al. Voxel-based morphometry detects cortical atrophy in the Parkinson variant of multiple system atrophy. Mov Disord 2003; 18 (10) 1132-1138
• 30 Boxer AL, Geschwind MD, Belfor N , et al. Patterns of brain atrophy that differentiate corticobasal degeneration syndrome from progressive supranuclear palsy. Arch Neurol 2006; 63 (1) 81-86
• 31 Josephs KA, Whitwell JL, Dickson DW , et al. Voxel-based morphometry in autopsy proven PSP and CBD. Neurobiol Aging 2008; 29 (2) 280-289
• 32 Chang CC, Chang YY, Chang WN , et al. Cognitive deficits in multiple system atrophy correlate with frontal atrophy and disease duration. Eur J Neurol 2009; 16 (10) 1144-1150
• 33 Mak E, Zhou J, Tan LC, Au WL, Sitoh YY, Kandiah N. Cognitive deficits in mild Parkinson's disease are associated with distinct areas of grey matter atrophy. J Neurol Neurosurg Psychiatry 2013;
• 34 Focke NK, Helms G, Scheewe S , et al. Individual voxel-based subtype prediction can differentiate progressive supranuclear palsy from idiopathic Parkinson syndrome and healthy controls. Hum Brain Mapp 2011; 32 (11) 1905-1915
• 35 Price S, Paviour D, Scahill R , et al. Voxel-based morphometry detects patterns of atrophy that help differentiate progressive supranuclear palsy and Parkinson's disease. Neuroimage 2004; 23 (2) 663-669
• 36 Vaillancourt DE, Spraker MB, Prodoehl J , et al. High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease. Neurology 2009; 72 (16) 1378-1384
• 37 Cochrane CJ, Ebmeier KP. Diffusion tensor imaging in parkinsonian syndromes: a systematic review and meta-analysis. Neurology 2013; 80 (9) 857-864
• 38 Nicoletti G, Lodi R, Condino F , et al. Apparent diffusion coefficient measurements of the middle cerebellar peduncle differentiate the Parkinson variant of MSA from Parkinson's disease and progressive supranuclear palsy. Brain 2006; 129 (Pt 10) 2679-2687
• 39 Paviour DC, Thornton JS, Lees AJ, Jäger HR. Diffusion-weighted magnetic resonance imaging differentiates Parkinsonian variant of multiple-system atrophy from progressive supranuclear palsy. Mov Disord 2007; 22 (1) 68-74
• 40 Baudrexel S, Seifried C, Penndorf B , et al. The value of putaminal diffusion imaging versus 18-fluorodeoxyglucose positron emission tomography for the differential diagnosis of the Parkinson variant of multiple system atrophy. Mov Disord 2014; 29 (Suppl. 03) 380-387
• 41 Tsukamoto K, Matsusue E, Kanasaki Y , et al. Significance of apparent diffusion coefficient measurement for the differential diagnosis of multiple system atrophy, progressive supranuclear palsy, and Parkinson's disease: evaluation by 3.0-T MR imaging. Neuroradiology 2012; 54 (9) 947-955
• 42 Erbetta A, Mandelli ML, Savoiardo M , et al. Diffusion tensor imaging shows different topographic involvement of the thalamus in progressive supranuclear palsy and corticobasal degeneration. AJNR Am J Neuroradiol 2009; 30 (8) 1482-1487
• 43 Griffiths PD, Crossman AR. Distribution of iron in the basal ganglia and neocortex in postmortem tissue in Parkinson's disease and Alzheimer's disease. Dementia 1993; 4 (2) 61-65
• 44 Lehéricy S, Sharman MA, Dos Santos CL, Paquin R, Gallea C. Magnetic resonance imaging of the substantia nigra in Parkinson's disease. Mov Disord 2012; 27 (7) 822-830
• 45 Han YH, Lee JH, Kang BM , et al. Topographical differences of brain iron deposition between progressive supranuclear palsy and parkinsonian variant multiple system atrophy. J Neurol Sci 2013; 325 (1-2) 29-35
• 46 Péran P, Cherubini A, Assogna F , et al. Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature. Brain 2010; 133 (11) 3423-3433
• 47 Lee JH, Han YH, Kang BM, Mun CW, Lee SJ, Baik SK. Quantitative assessment of subcortical atrophy and iron content in progressive supranuclear palsy and parkinsonian variant of multiple system atrophy. J Neurol 2013; 260 (8) 2094-2101
• 48 Wang Y, Butros SR, Shuai X , et al. Different iron-deposition patterns of multiple system atrophy with predominant parkinsonism and idiopathetic Parkinson diseases demonstrated by phase-corrected susceptibility-weighted imaging. AJNR Am J Neuroradiol 2012; 33 (2) 266-273
• 49 Lewis SJ, Shine JM, Duffy S, Halliday G, Naismith SL. Anterior cingulate integrity: executive and neuropsychiatric features in Parkinson's disease. Mov Disord 2012; 27 (10) 1262-1267
• 50 Nie K, Zhang Y, Huang B , et al. Marked N-acetylaspartate and choline metabolite changes in Parkinson's disease patients with mild cognitive impairment. Parkinsonism Relat Disord 2013; 19 (3) 329-334
• 51 Weiduschat N, Mao X, Beal MF, Nirenberg MJ, Shungu DC, Henchcliffe C. Usefulness of proton and phosphorus MR spectroscopic imaging for early diagnosis of Parkinson's disease. J Neuroimaging 2013;
• 52 Gröger A, Bender B, Wurster I, Chadzynski GL, Klose U, Berg D. Differentiation between idiopathic and atypical parkinsonian syndromes using three-dimensional magnetic resonance spectroscopic imaging. J Neurol Neurosurg Psychiatry 2013; 84 (6) 644-649
• 53 Guevara CA, Blain CR, Stahl D, Lythgoe DJ, Leigh PN, Barker GJ. Quantitative magnetic resonance spectroscopic imaging in Parkinson's disease, progressive supranuclear palsy and multiple system atrophy. Eur J Neurol 2010; 17 (9) 1193-1202
• 54 Tedeschi G, Litvan I, Bonavita S , et al. Proton magnetic resonance spectroscopic imaging in progressive supranuclear palsy, Parkinson's disease and corticobasal degeneration. Brain 1997; 120 (Pt 9) 1541-1552
• 55 Watanabe H, Fukatsu H, Katsuno M , et al. Multiple regional 1H-MR spectroscopy in multiple system atrophy: NAA/Cr reduction in pontine base as a valuable diagnostic marker. J Neurol Neurosurg Psychiatry 2004; 75 (1) 103-109
• 56 Morgen K, Sammer G, Weber L , et al. Structural brain abnormalities in patients with Parkinson disease: a comparative voxel-based analysis using T1-weighted MR imaging and magnetization transfer imaging. AJNR Am J Neuroradiol 2011; 32 (11) 2080-2086
• 57 Tambasco N, Belcastro V, Sarchielli P , et al. A magnetization transfer study of mild and advanced Parkinson's disease. Eur J Neurol 2011; 18 (3) 471-477
• 58 Eckert T, Sailer M, Kaufmann J , et al. Differentiation of idiopathic Parkinson's disease, multiple system atrophy, progressive supranuclear palsy, and healthy controls using magnetization transfer imaging. Neuroimage 2004; 21 (1) 229-235
• 59 Jokinen P, Helenius H, Rauhala E, Brück A, Eskola O, Rinne JO. Simple ratio analysis of 18F-fluorodopa uptake in striatal subregions separates patients with early Parkinson disease from healthy controls. J Nucl Med 2009; 50 (6) 893-899
• 60 Antonini A, Moresco RM, Gobbo C , et al. The status of dopamine nerve terminals in Parkinson's disease and essential tremor: a PET study with the tracer [11-C]FE-CIT. Neurol Sci 2001; 22 (1) 47-48
• 61 Oh M, Kim JS, Kim JY , et al. Subregional patterns of preferential striatal dopamine transporter loss differ in Parkinson disease, progressive supranuclear palsy, and multiple-system atrophy. J Nucl Med 2012; 53 (3) 399-406
• 62 Burn DJ, Sawle GV, Brooks DJ. Differential diagnosis of Parkinson's disease, multiple system atrophy, and Steele-Richardson-Olszewski syndrome: discriminant analysis of striatal 18F-dopa PET data. J Neurol Neurosurg Psychiatry 1994; 57 (3) 278-284
• 63 Ghaemi M, Hilker R, Rudolf J, Sobesky J, Heiss WD. Differentiating multiple system atrophy from Parkinson's disease: contribution of striatal and midbrain MRI volumetry and multi-tracer PET imaging. J Neurol Neurosurg Psychiatry 2002; 73 (5) 517-523
• 64 Bajaj N, Hauser RA, Grachev ID. Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with (123I) ioflupane in diagnosis of parkinsonian syndromes. J Neurol Neurosurg Psychiatry 2013; 84 (11) 1288-1295
• 65 Plotkin M, Amthauer H, Klaffke S , et al. Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients. J Neural Transm 2005; 112 (5) 677-692
• 66 Antonini A, Leenders KL, Vontobel P , et al. Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease. Brain 1997; 120 (Pt 12) 2187-2195
• 67 Van Laere K, Clerinx K, D'Hondt E, de Groot T, Vandenberghe W. Combined striatal binding and cerebral influx analysis of dynamic 11C-raclopride PET improves early differentiation between multiple-system atrophy and Parkinson disease. J Nucl Med 2010; 51 (4) 588-595
• 68 Vlaar AM, de Nijs T, Kessels AG , et al. Diagnostic value of 123I-ioflupane and 123I-iodobenzamide SPECT scans in 248 patients with parkinsonian syndromes. Eur Neurol 2008; 59 (5) 258-266
• 69 Broussolle E, Dentresangle C, Landais P , et al. The relation of putamen and caudate nucleus 18F-Dopa uptake to motor and cognitive performances in Parkinson's disease. J Neurol Sci 1999; 166 (2) 141-151
• 70 Brück A, Aalto S, Rauhala E, Bergman J, Marttila R, Rinne JO. A follow-up study on 6-[18F]fluoro-L-dopa uptake in early Parkinson's disease shows nonlinear progression in the putamen. Mov Disord 2009; 24 (7) 1009-1015
• 71 Hellwig S, Amtage F, Kreft A , et al. [¹⁸F]FDG-PET is superior to [¹²³I]IBZM-SPECT for the differential diagnosis of parkinsonism. Neurology 2012; 79 (13) 1314-1322
• 72 Zhao P, Zhang B, Gao S. 18F-FDG PET study on the idiopathic Parkinson's disease from several parkinsonian-plus syndromes. Parkinsonism Relat Disord 2012; 18 (Suppl. 01) S60-S62
• 73 Eidelberg D. Metabolic brain networks in neurodegenerative disorders: a functional imaging approach. Trends Neurosci 2009; 32 (10) 548-557
• 74 Holtbernd F, Eidelberg D. Functional brain networks in movement disorders: recent advances. Curr Opin Neurol 2012; 25 (4) 392-401
• 75 Eckert T, Tang C, Ma Y , et al. Abnormal metabolic networks in atypical parkinsonism. Mov Disord 2008; 23 (5) 727-733
• 76 Eidelberg D, Moeller JR, Dhawan V , et al. The metabolic topography of parkinsonism. J Cereb Blood Flow Metab 1994; 14 (5) 783-801
• 77 Poston KL, Tang CC, Eckert T , et al. Network correlates of disease severity in multiple system atrophy. Neurology 2012; 78 (16) 1237-1244
• 78 Ma Y, Tang C, Spetsieris PG, Dhawan V, Eidelberg D. Abnormal metabolic network activity in Parkinson's disease: test-retest reproducibility. J Cereb Blood Flow Metab 2007; 27 (3) 597-605
• 79 Tang CC, Poston KL, Eckert T , et al. Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis. Lancet Neurol 2010; 9 (2) 149-158
• 80 Jain S, Goldstein DS. Cardiovascular dysautonomia in Parkinson disease: from pathophysiology to pathogenesis. Neurobiol Dis 2012; 46 (3) 572-580
• 81 Rascol O, Schelosky L. 123I-metaiodobenzylguanidine scintigraphy in Parkinson's disease and related disorders. Mov Disord 2009; 24 (Suppl. 02) S732-S741
• 82 Yoshita M. Differentiation of idiopathic Parkinson's disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 meta-iodobenzylguanidine myocardial scintigraphy. J Neurol Sci 1998; 155 (1) 60-67
• 83 Braune S, Reinhardt M, Schnitzer R, Riedel A, Lücking CH. Cardiac uptake of [123I]MIBG separates Parkinson's disease from multiple system atrophy. Neurology 1999; 53 (5) 1020-1025
• 84 Courbon F, Brefel-Courbon C, Thalamas C , et al. Cardiac MIBG scintigraphy is a sensitive tool for detecting cardiac sympathetic denervation in Parkinson's disease. Mov Disord 2003; 18 (8) 890-897
• 85 Nagayama H, Hamamoto M, Ueda M, Nagashima J, Katayama Y. Reliability of MIBG myocardial scintigraphy in the diagnosis of Parkinson's disease. J Neurol Neurosurg Psychiatry 2005; 76 (2) 249-251
• 86 Eisensehr I, Linke R, Noachtar S, Schwarz J, Gildehaus FJ, Tatsch K. Reduced striatal dopamine transporters in idiopathic rapid eye movement sleep behaviour disorder. Comparison with Parkinson's disease and controls. Brain 2000; 123 (Pt 6) 1155-1160
• 87 Iranzo A, Valldeoriola F, Lomeña F , et al. Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. Lancet Neurol 2011; 10 (9) 797-805
• 88 Iranzo A, Lomeña F, Stockner H , et al; Sleep Innsbruck Barcelona (SINBAR) group. Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study [corrected]. Lancet Neurol 2010; 9 (11) 1070-1077
• 89 Holtbernd F, Gagnon JF, Postuma RB , et al. Abnormal metabolic network activity in REM sleep behavior disorder. Neurology 2014; 82 (7) 620-627